Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-Current Assets (2017 - 2025)

Cue Biopharma's Non-Current Assets history spans 9 years, with the latest figure at $5.8 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 22.89% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $29.1 million, down 17.76%, while the annual FY2024 figure was $7.1 million, 30.0% down from the prior year.
  • Non-Current Assets for Q3 2025 was $5.8 million at Cue Biopharma, down from $9.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $15.7 million in Q2 2022 and bottomed at $5.8 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $10.1 million (2023), against an average of $10.8 million.
  • The largest annual shift saw Non-Current Assets tumbled 33.97% in 2021 before it skyrocketed 69.37% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $14.9 million in 2021, then decreased by 5.6% to $14.1 million in 2022, then dropped by 28.52% to $10.1 million in 2023, then crashed by 30.0% to $7.1 million in 2024, then dropped by 17.41% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Non-Current Assets are $5.8 million (Q3 2025), $9.9 million (Q2 2025), and $6.3 million (Q1 2025).